cognitive cybersecurity intelligence

News and Analysis

Search

The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M

Tome Biosciences emerged from stealth with $213 million in financing and plans to create curative cell and gene therapies that correct genes in vivo. The company’s programmable genomic integration technology enables the insertion of any DNA sequence into any programmed genomic location. Initial projects include gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases. The company, which has almost 150 employees, plans to disclose clinical indications for its first therapies in 2024.

Source: www.genengnews.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

Risk Non-Payment or Deny Medications

A ransomware attack by the ‘Blackcat’ group on UnitedHealth Group subsidiary Change Healthcare has disrupted payment systems and prescription processing in nearly 90% of US